Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
- Oct 4, 2018Astellas Oncology Announces Grand Prize Winner of C3 Prize® at Union for International Cancer Control (UICC) World Cancer CongressThree innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic
Sep 25, 2018Astellas ranked in recognition of its commitment and support for working mothers
Sep 24, 2018Astellas recognized by Great Place to Work® Institute
Sep 24, 2018Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate CancerResults from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1)